• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Differences in cardiovascular safety with non ‐steroidal anti‐inflammatory drug therapy ‐ a nationwide study in patients with osteoarthritis
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - November 28, 2018 Category: Drugs & Pharmacology Authors: Carlo Alberto Barcella, Morten Lamberts, Patricia McGettigan, Emil Loldrup Fosb øl, Jesper Lindhardsen, Christian Torp‐Pedersen, Gunnar Hilmar Gislason, Anne‐Marie Schjerning Olsen Tags: Original Article Source Type: research

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses...
Source: The Rheumatologist - May 15, 2018 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Safety celecoxib Drug Safety fasinumab FDA hip knee Knee Osteoarthritis (OA) Nonsteroidal anti-inflammatory drugs (NSAIDs) Pain Pain Management U.S. Food and Drug Administration (FDA) Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)
This study excluded an increased risk of the primary endpoint of more than two events per 1000 patient-years associated with switching to prescribed celecoxib.Clinical Trial Registrationhttps://clinicaltrials.gov/show/NCT00447759; Unique identifier: NCT00447759.
Source: European Heart Journal - October 4, 2016 Category: Cardiology Source Type: research

Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs
Conclusion: From the analysis conducted, it appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound.
Source: Therapeutic Advances in Musculoskeletal Disease - August 4, 2014 Category: Orthopaedics Authors: Fabule, J., Adebajo, A. Tags: Original Research Source Type: research